{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T03:33:07Z","timestamp":1768534387163,"version":"3.49.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"11","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI103044 to R. R. K."],"award-info":[{"award-number":["K23AI103044 to R. R. K."]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,13]]},"DOI":"10.1093\/cid\/cix686","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T07:18:43Z","timestamp":1501571923000},"page":"1862-1871","source":"Crossref","is-referenced-by-count":11,"title":["Time to Sputum Culture Conversion and Treatment Outcomes Among Patients with Isoniazid-Resistant Tuberculosis in Atlanta, Georgia"],"prefix":"10.1093","volume":"65","author":[{"given":"Marcos C","family":"Schechter","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Destani","family":"Bizune","sequence":"additional","affiliation":[{"name":"Rollins School of Public Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Kagei","sequence":"additional","affiliation":[{"name":"Emory University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamuka","family":"Machaidze","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P","family":"Holland","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine"},{"name":"Communicable Disease Prevention Branch, Fulton County Health Department of Health and Wellness, Atlanta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alawode","family":"Oladele","sequence":"additional","affiliation":[{"name":"Dekalb County Board of Health, Decatur"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun F","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine"},{"name":"Department of Pathology, Grady Memorial Hospital, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina A","family":"Rebolledo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine"},{"name":"Rollins School of Public Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan M","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell R","family":"Kempker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"key\n\t\t\t\t20180306232538_CIT0001","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5588\/ijtld.16.0716","article-title":"Isoniazid-resistant tuberculosis: a cause for concern?","volume":"21","author":"Stagg","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180306232538_CIT0002","volume-title":"World Health Organization. Global Tuberculosis Report 2014","year":"2014"},{"key":"key\n\t\t\t\t20180306232538_CIT0003","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/ng.3767","article-title":"Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance","volume":"49","author":"Manson","year":"2017","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t20180306232538_CIT0004","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(16)30407-8","article-title":"Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis","volume":"17","author":"Gegia","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180306232538_CIT0005","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180306232538_CIT0006","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306232538_CIT0007","first-page":"423","article-title":"Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis","volume":"133","author":"Mitchison","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20180306232538_CIT0008","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1164\/ajrccm\/136.6.1339","article-title":"Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service\/British Medical Research Council","volume":"136","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20180306232538_CIT0009","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/cid\/cis487","article-title":"Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis","volume":"55","author":"Dooley","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306232538_CIT0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1056\/NEJMe1511990","article-title":"Chemotherapy for tuberculous meningitis","volume":"374","author":"Donald","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180306232538_CIT0011","doi-asserted-by":"crossref","first-page":"644","DOI":"10.5588\/ijtld.12.0380","article-title":"Can mycobacterial katG genetic changes in isoniazid-resistant tuberculosis influence human disease features?","volume":"17","author":"Escalante","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180306232538_CIT0012","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.5588\/ijtld.16.0148","article-title":"Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutation","volume":"20","author":"Otto-Knapp","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180306232538_CIT0013","volume-title":"World Health Organization. WHO Treatment Guidelines for Drug-Resistant Tuberculosis\u20142016 Update. Geneva, Switzerland: World Health Organization; 2016"},{"key":"key\n\t\t\t\t20180306232538_CIT0014","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1164\/rccm.200305-682OC","article-title":"The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis","volume":"168","author":"Gosling","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180306232538_CIT0015","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-dose rifapentine with moxifloxacin for pulmonary tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180306232538_CIT0016","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1086\/595689","article-title":"Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis","volume":"48","author":"Cattamanchi","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306232538_CIT0017","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmi.2014.08.008","article-title":"Treatment outcome of patients with isoniazid mono-resistant tuberculosis","volume":"21","author":"Chien","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180306232538_CIT0018","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/AAC.01377-15","article-title":"Treatment outcomes with fluoroquinolone-containing regimens for isoniazid-resistant pulmonary tuberculosis","volume":"60","author":"Lee","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306232538_CIT0019","volume-title":"US Department of Health and Human Services, Food and Drug Administration. Pulmonary Tuberculosis: Developing Drugs for Treatment","year":"2013"},{"key":"key\n\t\t\t\t20180306232538_CIT0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S2213-2600(15)00036-3","article-title":"Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies","volume":"3","author":"Kurbatova","year":"2015","journal-title":"Lancet Respir Med"},{"key":"key\n\t\t\t\t20180306232538_CIT0021","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/0033354917694008","article-title":"Outbreak of drug-resistant Mycobacterium tuberculosis among homeless people in Atlanta, Georgia, 2008\u20132015","volume":"132","author":"Powell","year":"2017","journal-title":"Public Health Rep"},{"key":"key\n\t\t\t\t20180306232538_CIT0022","first-page":"723","article-title":"Centers for Disease Control and Prevention (CDC). Tuberculosis genotyping\u2014United States, 2004\u20132010","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20180306232538_CIT0023","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"key\n\t\t\t\t20180306232538_CIT0024","article-title":"Applied Survival Analysis Regression Modeling of Time-to-Event Data","author":"Hosmer","year":"2008"},{"key":"key\n\t\t\t\t20180306232538_CIT0025","volume-title":"Centers for Disease Control and Prevention (CDC). Reported Tuberculosis in the United States, 2015","year":"2016"},{"key":"key\n\t\t\t\t20180306232538_CIT0026","volume-title":"The Use of Molecular Line Probe Assay for the Detection of Resistance to Isoniazid and Rifampicin: Policy Update","author":"World Health Organization","year":"2016"},{"key":"key\n\t\t\t\t20180306232538_CIT0027","volume-title":"Curry International Tuberculosis Center, California Department of Public Health. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 3rd ed","year":"2016"},{"key":"key\n\t\t\t\t20180306232538_CIT0028","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1378\/chest.119.6.1730","article-title":"Treatment of isoniazid-resistant tuberculosis in southeastern Texas","volume":"119","author":"Escalante","year":"2001","journal-title":"Chest"},{"key":"key\n\t\t\t\t20180306232538_CIT0029","doi-asserted-by":"crossref","first-page":"e86316","DOI":"10.1371\/journal.pone.0086316","article-title":"Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180306232538_CIT0030","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","author":"Mitchison","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180306232538_CIT0031","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200210-1125OC","article-title":"Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days","volume":"167","author":"Jindani","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180306232538_CIT0032","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.tube.2010.07.003","article-title":"The chemotherapy of tuberculous meningitis in children and adults","volume":"90","author":"Donald","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"key\n\t\t\t\t20180306232538_CIT0033","first-page":"401","article-title":"The long-term mortality of tuberculosis meningitis patients in New York City: a cohort study","volume":"64","author":"Vinnard","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306232538_CIT0034","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1128\/AAC.01474-09","article-title":"New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic\/pharmacodynamic science and population pharmacokinetic variability","volume":"54","author":"Gumbo","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306232538_CIT0035","first-page":"484","article-title":"Shortening tuberculosis treatment with fluoroquinolones: lost in translation?","volume":"62","author":"Lanoix","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306232538_CIT0036","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/0033354917698117","article-title":"Sociodemographic and clinical risk factors associated with tuberculosis mortality in the United States, 2009\u20132013","volume":"132","author":"Hannah","year":"2017","journal-title":"Public Health Rep"},{"key":"key\n\t\t\t\t20180306232538_CIT0037","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/65\/11\/1862\/24267021\/cix686.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T23:26:28Z","timestamp":1520378788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/65\/11\/1862\/4061437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,8,3]]},"published-print":{"date-parts":[[2017,11,13]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix686","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,12,1]]},"published":{"date-parts":[[2017,8,3]]}}}